InsiderTrades.com logo
Sushil Patel net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Sushil Patel Biography and Net Worth

CEO of Replimune Group

Sushil Patel joined Replimune as Chief Commercial Officer in May 2021 and transitioned to Chief Strategy Officer in December of 2022 and then Chief Executive Office in April of 2024. Sushil brings move than 20 years of experience in the biotech industry including pre- and post-launch commercialization strategy and execution in both US and global markets. Most recently he served as the Franchise Head for Lung, Skin, Tumor Agnostic, and Rare Cancers within Global Product Strategy at Genentech. Previously to that he served as the global launch lead and lifecycle leader for Tecentriq in lung cancer. He has been involved in more than 8 product launches (>20 indications) in various roles of increasing responsibility across marketing, sales, and franchise management. Prior to joining Genentech, he worked as a strategic management consultant and at IMS Health in their Pharma Strategy Group. Sushil is a member of the board of directors of Revolution Medicines, a clinical stage oncology company developing novel targeted therapies for RAS-addicted cancers, since June 2022. Sushil obtained a PhD in Molecular Biology and a Master of Sciences in Biotechnology from the Imperial College of Science, Technology and Medicine, University of London.

What is Sushil Patel's net worth?

The estimated net worth of Sushil Patel is at least $1.56 million as of December 16th, 2024. Patel owns 202,014 shares of Replimune Group stock worth more than $1,557,528 as of May 12th. This net worth estimate does not reflect any other investments that Patel may own. Additionally, Patel receives a salary of $665,050.00 as CEO at Replimune Group. Learn More about Sushil Patel's net worth.

How old is Sushil Patel?

Patel is currently 53 years old. There are 7 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Sushil Patel's age.

What is Sushil Patel's salary?

As the CEO of Replimune Group, Inc., Patel earns $665,050.00 per year. There are 2 executives that earn more than Patel. The highest earning executive at Replimune Group is Mr. Philip Astley-Sparke F.S.A., CEO & Director, who commands a salary of $1,070,000.00 per year. Learn More on Sushil Patel's salary.

How do I contact Sushil Patel?

The corporate mailing address for Patel and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at ir@replimune.com. Learn More on Sushil Patel's contact information.

Has Sushil Patel been buying or selling shares of Replimune Group?

Sushil Patel has not been actively trading shares of Replimune Group in the last ninety days. Most recently, Sushil Patel sold 10,000 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a transaction totalling $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at $2,509,013.88. Learn More on Sushil Patel's trading history.

Who are Replimune Group's active insiders?

Replimune Group's insider roster includes Philip Astley-Sparke (Chairman), Robert Coffin (Insider), Pamela Esposito (Insider), Emily Hill (CFO), Colin Love (COO), Sushil Patel (CEO), Christopher Sarchi (Insider), Andrew Schwendenman (CAO), and Konstantinos Xynos (Chief Medical Officer). Learn More on Replimune Group's active insiders.

Are insiders buying or selling shares of Replimune Group?

During the last year, insiders at the sold shares 10 times. They sold a total of 133,782 shares worth more than $1,005,817.21. The most recent insider tranaction occured on December, 16th when CEO Sushil Patel sold 10,000 shares worth more than $124,200.00. Insiders at Replimune Group own 8.8% of the company. Learn More about insider trades at Replimune Group.

Information on this page was last updated on 12/16/2024.

Sushil Patel Insider Trading History at Replimune Group

See Full Table

Sushil Patel Buying and Selling Activity at Replimune Group

This chart shows Sushil Patel's buying and selling at Replimune Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Replimune Group Company Overview

Replimune Group logo
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $7.93
Low: $7.86
High: $8.28

50 Day Range

MA: $9.36
Low: $6.92
High: $12.29

2 Week Range

Now: $7.93
Low: $4.92
High: $17.00

Volume

33,034 shs

Average Volume

896,018 shs

Market Capitalization

$610.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68